Stock listing

LSE:0A8U Synlogic Inc Share Price

UK listing (LSE) of Synlogic Inc · home listing OTC:SYBX

Follow Synlogic Inc into a list and get an email when it puts out news.

Share price · LSE:0A8U

$0.96 USD -0.14 (-12.7%)

Close on Nov 20, 2026

Past year -42.9% · daily closes, Nov 20, 2025 – Nov 4, 2026, adjusted for splits
Day range
$0.96 – $0.96 USDNov 20, 2026
Volume
4,800 sharesNov 20, 2026
52-week range
$0.54 – $1.63 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$668 USDMedian day 7 shares · 5 days with no trades · last 3 months, Sep 2, 2026 – Nov 4, 2026
Synlogic Inc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
OTC:SYBX · Home$0.96 USD-0.023 (-2.4%)4,352$0.96$0.967$0.96$0.984Close on Nov 20, 2026
LSE:0A8U$0.96 USD-0.14 (-12.7%)4,800$0.96$0.96$0.96$1.10Close on Nov 20, 2026

Daily closes

Last 3 months, Sep 2, 2026 – Nov 4, 2026 · LSE:0A8U · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.93-0.03-3.1%$0.93$0.93$0.93140
$0.960.000.0%$0.96$0.96$0.960
$0.960.000.0%$0.96$0.96$0.960
$0.96-0.005-0.5%$0.965$0.965$0.96949
$0.9650.000.0%$0.965$0.965$0.9650
$0.9650.000.0%$0.965$0.965$0.9650
$0.9650.000.0%$0.965$0.965$0.9650
$0.965-0.035-3.5%$0.965$0.965$0.9659
$1.00-0.07-6.5%$1.00$1.00$1.00994
$1.070.000.0%$1.07$1.07$1.074
$1.07-0.04-3.6%$1.10$1.11$1.071
$1.110.000.0%$1.10$1.11$1.10300
$1.11-0.05-4.3%$1.11$1.11$1.112,806
$1.16+0.01+0.9%$1.13$1.16$1.135,513
$1.15-0.02-1.7%$1.12$1.15$1.12899
$1.17+0.02+1.7%$1.17$1.17$1.17100
$1.15-0.09-7.3%$1.15$1.15$1.152
$1.24+0.09+7.8%$1.24$1.24$1.242
$1.15-0.23-16.7%$1.15$1.15$1.15270
$1.38+0.15+12.2%$1.25$1.38$1.251

Splits

1 split · LSE:0A8U · every price before a split is adjusted for it

DayRatioWhat
1-for-15Consolidation
Ticker
LSE:0A8U
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
USD

Synlogic Inc on 6ix

Sector
Health care
Industry
Biotechnology
Calls
8 calls with a replay · 8 with a transcript · latest Aug 11, 2022
Decks
26 decks · latest Jan 17, 2024

Where Synlogic Inc is listed

ListingExchangeCountryCurrency
OTC:SYBX · Home listingOTCUnited StatesUSD
LSE:0A8U · This pageLSEUnited KingdomUSD

Valuation

Price/book 1.2× against a median of 4.5×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$201,442 USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
1.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.50

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Synlogic Inc · OTC:SYBXUS$11.76MUS$201,442n/an/an/a1.2×n/a0.0×0.50
Genflow Biosciences PLC · LSE:GENFUS$12.06MUS$11.23Mn/an/an/a48.5×n/a0.0×n/a
BioCardia, Inc. · NASDAQ:BCDAUS$11.88MUS$10.22Mn/an/an/a14.2×n/a0.7×0.42
Xintela AB · OMXSTO:XINTUS$11.88MUS$11.81Mn/a39.8×n/an/an/an/an/a
Pluri Inc. · NASDAQ:PLURUS$11.85MUS$38.65Mn/a26.5×n/an/an/an/a0.53
Imugene Ltd · ASX:IMUUS$11.74MUS$14.16Mn/an/an/a2.0×n/a0.7×n/a
Radiopharm Theranostics Limited · ASX:RADUS$11.59MUS$8.85Mn/a4.8×n/a0.7×n/a0.0×n/a
Aelis Farma SA · EURONEXT:AELISUS$11.55MUS$9.09Mn/a4.0×n/a4.5×−308.7%1.9×n/a
Simris Group AB Class B · OMXSTO:SIMRIS_BUS$11.54MUS$19.53Mn/a144×n/a154×n/a117×n/a
Dyadic International, Inc. · NASDAQ:DYAIUS$11.51MUS$12.03Mn/a3.9×n/an/a−226.9%n/a1.12
Psyence Biomedical Ltd. · NASDAQ:PBMUS$11.33MUS$4.18Mn/an/an/a0.9×n/a0.0×0.90
Median of the othersUS$11.66MUS$11.52M15.7×4.5×−267.8%0.7×0.72

Forecasts

1 hold · Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
1.00 USD · Analysts' mean

Team and board

Officers

OfficerRole
Aoife BrennanPresident and Chief Executive Officer
Mary Beth DooleyPrincipal Executive Officer and Principal Financial Officer

Board

DirectorRole
Peter BarrettChairman, Partner, Atlas Venture

Events

Calls

CallWhenStatus
Synlogic (OTC:SYBX) Q2 2022 Earnings CallThu, Aug 11, 2022 · 8:30 AM ETReplay
Synlogic (OTC:SYBX) Q1 2022 Earnings CallThu, May 12, 2022 · 8:30 AM ETReplay
Synlogic (OTC:SYBX) Q4 2021 Earnings CallThu, Mar 17, 2022 · 8:30 AM ETReplay
Synlogic (OTC:SYBX) Q3 2021 Earnings CallWed, Nov 10, 2021 · 8:30 AM ETReplay
Synlogic (OTC:SYBX) Q2 2021 Earnings CallThu, Aug 12, 2021 · 8:30 AM ETReplay
Synlogic (OTC:SYBX) Q1 2021 Earnings CallThu, May 13, 2021 · 8:30 AM ETReplay
Synlogic (OTC:SYBX) Q4 2020 Earnings CallThu, Mar 25, 2021 · 8:30 AM ETReplay
Synlogic (OTC:SYBX) Q3 2020 Earnings CallThu, Nov 05, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026
Q2 2026Aug 12, 2026+4.2%
Q1 2026May 29, 2026+3.0%
Q4 2025Mar 17, 2026+9.4%
Q3 2025Nov 13, 20250.0%
Q2 2025Aug 7, 2025+1.4%
Q1 2025May 12, 2025 · Before open+0.5%
Q4 2024Mar 6, 2025 · After close+0.4%
Q3 2024Nov 12, 2024 · After close−3.4%
Q2 2024Aug 8, 2024 · Before open−4.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open−2.8%
Q4 2023Mar 19, 2024 · Before open−6.3%
Q3 2023Nov 9, 2023 · Before open−15.0%
Q2 2023Aug 10, 2023 · Before open+1.5%
Q1 2023May 11, 2023 · Before open+0.5%
Q4 2022Mar 29, 2023 · Before open+2.9%
Q3 2022Nov 10, 2022 · Before open−6.9%
Q2 2022Aug 11, 2022 · Before open+11.2%
Q1 2022May 12, 2022 · Before open−14.4%
Q4 2021Mar 17, 2022 · Before open−4.7%

Open Events

Decks

DeckKindSlidesDate
Sidoti Micro-Cap Virtual Conference 2024Conference14 slidesJan 17, 2024
Investor Presentation (January 2024)Investor deck33 slidesJanuary 2024
Technical Presentation (December 2022)Technical26 slidesDec 15, 2022
Technical Presentation (October 2022)Technical24 slidesOct 18, 2022
FY2021 Earnings PresentationEarnings22 slidesMar 17, 2022
Q3 2021 Earnings PresentationEarnings25 slidesNov 10, 2021
Investor Presentation (September 2021)Investor deck49 slidesSep 20, 2021
Corporate Update (September 2021)Corporate update29 slidesSep 20, 2021
Investor Presentation (August 2021)Investor deck43 slidesAug 12, 2021
Q2 2021 Earnings PresentationEarnings20 slidesAug 12, 2021
All 26 decks
DeckKindSlidesDate
Investor Presentation (March 2021)Investor deck46 slidesMar 25, 2021
Q4 2020 Earnings PresentationEarnings18 slidesMar 25, 2021
Q3 2020 Earnings PresentationEarnings17 slidesNov 5, 2020
Q2 2020 Earnings PresentationEarnings16 slidesAug 6, 2020
Investor Presentation (August 2019)Investor deck34 slidesAug 20, 2019
2019 Wedbush PacGrow Healthcare ConferenceConference29 slidesAug 13, 2019
Investor Presentation (June 2019)Investor deck36 slidesJun 12, 2019
Q1 2019 Earnings PresentationEarnings7 slidesMay 9, 2019
Investor Presentation (March 2019)Investor deck34 slidesMar 20, 2019
Investor Presentation (January 2019)Investor deck36 slidesJan 7, 2019
Investor Presentation (November 2018)Investor deck35 slidesNov 19, 2018
SITC 2018Conference63 slidesNov 13, 2018
H. C. Wainwright 20th Annual Global Investment Conference (September 2018)Conference28 slidesSep 5, 2018
Technical Presentation (September 2018)Technical10 slidesSep 4, 2018
Investor Presentation (January 2018)Investor deck45 slidesJan 8, 2018
Mirna Therapeutics — Merger or Acquisition (June 2017)Merger or acquisition25 slidesJun 9, 2017

Open Decks

IPO

Went public as Mirna Therapeutics, Inc. Priced at US$7.00 a share on Sep 30, 2015.

Price
US$7.00 a share
Shares offered
6,250,000 shares of common stock
Offering size
US$43.8 million
Underwriters' option
Up to 937,500 more shares
Listing
MIRN on the Nasdaq Global Market
Underwriters
Citigroup, Leerink Partners, Oppenheimer & Co., Cantor Fitzgerald & Co. · In the order on the cover
Shares delivered
On or about Oct 6, 2015

Steps

StepWhen
Draft sent to the SEC in confidenceMar 12, 2014
Filed publiclyAug 24, 2015
Amended 5 timesNewest Sep 30, 2015
Shares registered with an exchangeSep 23, 2015
Declared effective by the SECSep 30, 2015
Final prospectus, with the priceOct 1, 2015

Open IPO · From the cover of the final prospectus (424B4) filed Oct 1, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue08.00K3.37M1.18M1.75M545.0K2.22M2.52M2.44M444.0K
Research and development43.0K9.15M44.0M52.0M47.1M47.5M41.9M38.0M30.3M15.0M
Operating income-4.01M-41.0M-55.2M-67.4M-60.8M-60.5M-54.4M-51.2M-40.8M-21.0M
Depreciation and amortization0347.0K1.96M2.52M2.44M2.64M2.70M2.42M2.31M159.0K
EBITDA-4.01M-40.6M-53.2M-64.9M-58.3M-57.8M-51.7M-48.8M-38.5M-20.8M
Interest expense01.00K2.00K2.00K6.00K21.0K43.0K57.0K7.00K
Income before tax-1.00M-23.4M-61.3M-66.1M
Income tax05.00K14.0K000000
Net income-1.00M-23.4M-61.3M-66.1M-60.6M-59.2M-51.4M-48.4M-40.4M-21.0M
Earnings per share, basic-0.08-1.92-9.42-13.83-1.09-1.65-1.70-2.03-6.00-1.26
Earnings per share, diluted-0.08-1.92-9.42-13.83-1.09-1.65-1.70-2.03-6.00-1.26

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents14.7M18.9M24.0M15.9M16.4M32.5M26.2M11.3M58.4M14.6M
Short-term investments023.8M61.8M112.2M67.9M93.4M111.5M28.6M
Current assets15.4M19.8M49.9M79.8M133.3M106.8M133.2M124.3M88.6M16.1M
Property, plant and equipment05.60M7.32M9.09M10.8M13.0M14.8M9.78M3.50M
Total assets15.4M19.8M75.5M110.9M174.7M143.8M188.6M140.3M99.7M20.0M
Accounts payable103.0K164.0K1.46M1.78M1.94M2.00M2.17M2.42M2.68M988.0K
Current liabilities3.58M7.08M30.3M12.1M10.1M8.30M8.86M8.34M9.03M4.19M
Total liabilities3.81M
Shareholders' equity11.9M12.8M32.8M82.6M147.3M115.1M156.9M124.1M85.0M8.50M
Shares outstanding11.7M11.7M9.19M4.45M69.7M38.2M32.3M25.4M16.3M0

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-4.36M-31.7M-51.6M-56.9M-52.2M-39.6M-75.5M-42.5M-31.1M-20.4M
Capital spending0-14.0K-214.0K-728.0K-679.0K-395.0K-1.25M-5.65M-2.58M-1.84M
Free cash flow-4.36M-31.7M-51.8M-57.6M-52.9M-39.9M-76.7M-48.1M-33.6M-22.2M
Cash from investing167.0K25.3M38.8M58.4M-53.3M32.5M10.8M-87.2M9.28M-1.83M
Cash from financing0172.0K20.9M-2.04M89.4M13.4M79.6M82.5M66.7M30.6M
Change in cash-4.19M-6.15M8.10M-577.0K-16.1M6.32M14.9M-47.2M44.9M8.41M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
425Nov 5, 2026Other filingsSEC
425Nov 2, 2026Other filingsSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 29, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 29, 2026Big-stake noticeSEC
425Jul 29, 2026Other filingsSEC
8-K · Current reportJul 29, 2026Material contractSEC
25-NSEMay 18, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
10-K/A · Annual report, amendedApr 30, 2026Annual reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 6, 2026Big-stake noticeSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K/A · Current report, amendedJan 29, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 23, 2026Big-stake noticeSEC
8-K · Current reportJan 20, 2026Current reportSEC
8-K · Current reportDec 15, 2025Management or board changeSEC
8-K · Current reportNov 26, 2025Current reportSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersNov 12, 2025Annual reportSEC
DEF 14A · Proxy statementNov 12, 2025Meeting noticeSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 21, 2025Other filingsSEC
CORRESP · Letter to the SECAug 18, 2025Other filingsSEC
S-3/A · Registration statement, amendedAug 15, 2025Offer documentSEC
UPLOAD · Letter from the SECAug 13, 2025Other filingsSEC
S-3 · Registration statementAug 8, 2025Offer documentSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
10-K/A · Annual report, amendedApr 30, 2025Annual reportSEC
4 · Change in ownershipApr 29, 2025Insider tradeSEC
4 · Change in ownershipApr 29, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 25, 2025Big-stake noticeSEC
8-K · Current reportFeb 21, 2025Management or board changeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
8-K · Current reportJan 14, 2025Management or board changeSEC
8-K · Current reportDec 20, 2024Management or board changeSEC
8-K · Current reportDec 4, 2024Meeting outcomeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansNov 12, 2024Offer documentSEC
S-8 · Registration statement for employee plansNov 12, 2024Offer documentSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
DEF 14A · Proxy statementNov 5, 2024Meeting noticeSEC
ARS · Annual report to shareholdersNov 5, 2024Annual reportSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
8-K · Current reportAug 8, 2024ResultsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
SC 13D/A · Big-stake notice, amendedMay 16, 2024Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
10-K/A · Annual report, amendedApr 29, 2024Annual reportSEC
144 · Notice of proposed saleApr 22, 2024Other filingsSEC
SC 13G · Big-stake noticeApr 18, 2024Big-stake noticeSEC
4 · Change in ownershipApr 4, 2024Insider tradeSEC
4 · Change in ownershipApr 4, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 21, 2024Insider tradeSEC
4 · Change in ownershipMar 21, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 21, 2024Insider tradeSEC
8-K · Current reportMar 21, 2024Management or board changeSEC
144 · Notice of proposed saleMar 21, 2024Other filingsSEC
10-K · Annual reportMar 19, 2024Annual reportSEC
8-K · Current reportMar 19, 2024ResultsSEC
8-K · Current reportFeb 22, 2024Management or board changeSEC
8-A12B · Registration of shares for listing on an exchangeFeb 20, 2024Other filingsSEC
8-K · Current reportFeb 20, 2024Material contractSEC
3 · Initial statement of ownershipFeb 16, 2024Insider tradeSEC
SC 13D · Big-stake noticeFeb 16, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
8-K · Current reportFeb 12, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
8-K · Current reportDec 29, 2023Management or board changeSEC
8-K · Current reportNov 17, 2023Management or board changeSEC
4 · Change in ownershipNov 14, 2023Insider tradeSEC
4 · Change in ownershipNov 14, 2023Insider tradeSEC
4 · Change in ownershipNov 14, 2023Insider tradeSEC
8-K · Current reportNov 14, 2023Management or board changeSEC
8-K · Current reportNov 9, 2023ResultsSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 7, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedOct 13, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 13, 2023Big-stake noticeSEC
3 · Initial statement of ownershipOct 6, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedOct 4, 2023Big-stake noticeSEC
424B4 · ProspectusOct 2, 2023Offer documentSEC
8-K · Current reportSep 29, 2023Material contractSEC
EFFECT · Notice that a registration is effectiveSep 29, 2023Other filingsSEC
S-1MEF · Registration of more shares for the same offeringSep 28, 2023Offer documentSEC
8-K · Current reportSep 28, 2023Current reportSEC
S-1/A · Registration statement, amendedSep 28, 2023Offer documentSEC
CORRESP · Letter to the SECSep 26, 2023Other filingsSEC
CORRESP · Letter to the SECSep 26, 2023Other filingsSEC
S-1/A · Registration statement, amendedSep 26, 2023Offer documentSEC
UPLOAD · Letter from the SECSep 25, 2023Other filingsSEC
8-K · Current reportSep 22, 2023Meeting outcomeSEC
CORRESP · Letter to the SECSep 20, 2023Other filingsSEC
UPLOAD · Letter from the SECSep 15, 2023Other filingsSEC
UPLOAD · Letter from the SECSep 11, 2023Other filingsSEC
S-1 · Registration statementSep 8, 2023Offer documentSEC
DEF 14A · Proxy statementSep 1, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementAug 21, 2023Meeting noticeSEC
8-K · Current reportAug 16, 2023Material contractSEC
8-K · Current reportAug 10, 2023ResultsSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
4 · Change in ownershipJun 26, 2023Insider tradeSEC
8-K · Current reportJun 15, 2023Meeting outcomeSEC
8-K · Current reportJun 5, 2023Current reportSEC
8-K · Current reportMay 11, 2023ResultsSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
ARS · Annual report to shareholdersMay 1, 2023Annual reportSEC
DEFA14A · Additional proxy materialMay 1, 2023Meeting noticeSEC
DEF 14A · Proxy statementMay 1, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 21, 2023Meeting noticeSEC
4 · Change in ownershipApr 5, 2023Insider tradeSEC
4 · Change in ownershipApr 5, 2023Insider tradeSEC
4 · Change in ownershipApr 5, 2023Insider tradeSEC
424B5 · ProspectusApr 4, 2023Offer documentSEC
S-8 · Registration statement for employee plansMar 29, 2023Offer documentSEC
S-8 · Registration statement for employee plansMar 29, 2023Offer documentSEC
8-K · Current reportMar 29, 2023ResultsSEC
10-K · Annual reportMar 29, 2023Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 20, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeJan 20, 2023Big-stake noticeSEC
8-K · Current reportJan 19, 2023Current reportSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
4 · Change in ownershipJan 4, 2023Insider tradeSEC
8-K · Current reportDec 15, 2022Current reportSEC
8-K · Current reportDec 9, 2022Current reportSEC
8-K · Current reportNov 30, 2022Current reportSEC
8-K · Current reportNov 23, 2022Material contractSEC
10-Q · Quarterly reportNov 10, 2022Quarterly reportSEC
8-K · Current reportNov 10, 2022ResultsSEC
8-K · Current reportOct 18, 2022Current reportSEC
8-K · Current reportSep 6, 2022Current reportSEC
8-K · Current reportAug 11, 2022ResultsSEC
10-Q · Quarterly reportAug 11, 2022Quarterly reportSEC
4 · Change in ownershipJun 13, 2022Insider tradeSEC
4 · Change in ownershipJun 13, 2022Insider tradeSEC
4 · Change in ownershipJun 13, 2022Insider tradeSEC
4 · Change in ownershipJun 13, 2022Insider tradeSEC
4 · Change in ownershipJun 13, 2022Insider tradeSEC
4 · Change in ownershipJun 13, 2022Insider tradeSEC
4 · Change in ownershipJun 13, 2022Insider tradeSEC
4 · Change in ownershipJun 13, 2022Insider tradeSEC
8-K · Current reportJun 13, 2022Meeting outcomeSEC
4 · Change in ownershipMay 25, 2022Insider tradeSEC
8-K · Current reportMay 12, 2022ResultsSEC
10-Q · Quarterly reportMay 12, 2022Quarterly reportSEC
DEFA14A · Additional proxy materialApr 27, 2022Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2022Meeting noticeSEC
4 · Change in ownershipApr 6, 2022Insider tradeSEC
4 · Change in ownershipApr 6, 2022Insider tradeSEC
S-8 · Registration statement for employee plansMar 17, 2022Offer documentSEC
S-8 · Registration statement for employee plansMar 17, 2022Offer documentSEC
8-K · Current reportMar 17, 2022ResultsSEC
10-K · Annual reportMar 17, 2022Annual reportSEC
4 · Change in ownershipMar 3, 2022Insider tradeSEC
3 · Initial statement of ownershipMar 3, 2022Insider tradeSEC
8-K · Current reportMar 3, 2022Management or board changeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2022Big-stake noticeSEC
4 · Change in ownershipFeb 8, 2022Insider tradeSEC
4 · Change in ownershipFeb 8, 2022Insider tradeSEC
4 · Change in ownershipFeb 1, 2022Insider tradeSEC
8-K · Current reportJan 24, 2022Material contractSEC
4 · Change in ownershipJan 5, 2022Insider tradeSEC
8-K · Current reportNov 10, 2021ResultsSEC
10-Q · Quarterly reportNov 10, 2021Quarterly reportSEC
8-K · Current reportNov 9, 2021Current reportSEC
SC 13G · Big-stake noticeOct 1, 2021Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedSep 29, 2021Big-stake noticeSEC
8-K · Current reportSep 23, 2021Material contractSEC
424B5 · ProspectusSep 23, 2021Offer documentSEC
424B5 · ProspectusSep 22, 2021Offer documentSEC
8-K · Current reportSep 20, 2021Current reportSEC
8-K · Current reportAug 12, 2021ResultsSEC
10-Q · Quarterly reportAug 12, 2021Quarterly reportSEC
EFFECT · Notice that a registration is effectiveAug 2, 2021Other filingsSEC
8-K · Current reportJul 30, 2021Management or board changeSEC
CORRESP · Letter to the SECJul 29, 2021Other filingsSEC
UPLOAD · Letter from the SECJul 28, 2021Other filingsSEC
S-3 · Registration statementJul 23, 2021Offer documentSEC
8-K · Current reportJul 15, 2021Current reportSEC
8-K · Current reportJun 17, 2021Material contractSEC
4 · Change in ownershipJun 14, 2021Insider tradeSEC

This page holds 200 of 628 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Synlogic Inc’s releases · as of Nov 3, 2026

Common shares
12,248,950
Fully diluted
12,248,950

Fully diluted

LineSharesAs of
Common shares12,248,950Nov 3, 2026

Share count over time

CountShares
Nov 3, 202612,248,950

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
DRW Securities, LLC23,7630.19%US$26,614Sep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James Flynn
Other companies: Lite Strategy, Inc. (Director · Since at least Oct 31, 2023); Nuvalent, Inc. (Director · Since at least Jul 28, 2021); Larimar Therapeutics, Inc. (Director · Since at least May 28, 2020); BiomX Inc. (Director · Mar 15, 2024 – Apr 21, 2025 · Past); Oruka Therapeutics, Inc. (Director · Jan 30, 2024 – Jan 30, 2024 · Past); RiceBran Technologies (Director · Jan 3, 2024 – Jan 3, 2024 · Past); CareMax Inc (Director · Nov 17, 2022 – Nov 17, 2023 · Past); ARS Pharmaceuticals, Inc. (Director · Nov 8, 2022 – Nov 8, 2022 · Past); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Oncorus Inc (Director · Oct 1, 2020 – Feb 17, 2021 · Past); Acutus Medical Inc. (Director · Aug 5, 2020 – Jan 27, 2025 · Past); Deerfield Healthcare Technology Acquisitions Corp (Director · Jul 16, 2020 – Jul 21, 2020 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 6, 2019 · Past); AdaptHealth Corp. (Director · Feb 15, 2018 – Nov 8, 2019 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Sep 12, 2016 · Past); AveXis Inc (Director · Sep 3, 2015 – Feb 10, 2016 · Past)
Director · Mar 19, 2024 – Apr 26, 2025 · Past
Edward Mathers
Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); MBX Biosciences, Inc. (Director · Since at least Sep 12, 2024); Senti Biosciences Holdings, Inc. (Director · Since at least Jun 8, 2022); OnKure Therapeutics, Inc. (Director · Since at least Apr 8, 2021); Trevi Therapeutics, Inc. (Director · Since at least May 7, 2019); Rhythm Pharmaceuticals, Inc. (Director · Since at least Oct 4, 2017); Inozyme Pharma Inc (Director · Jul 23, 2020 – Jun 18, 2024 · Past); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Mirum Pharmaceuticals, Inc. (Director · Jul 17, 2019 – Jun 2, 2022 · Past); Ra Pharmaceuticals Inc (Director · Jun 28, 2018 – Apr 2, 2020 · Past)
Director · Dec 29, 2017 – Jun 22, 2023 · Past
Andrew Gengos
Other companies: Immuneering Corporation (Chief Financial Officer and Treasurer · Since at least Jul 16, 2026); Turn Therapeutics Inc. (Director · Since at least Oct 7, 2025); Terns Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Feb 24, 2025); LeonaBio, Inc. (CFO and Chief Business Officer · May 18, 2023 – Sep 3, 2024 · Past); Cyteir Therapeutics Inc (Chief Business Officer · Jun 17, 2021 – Feb 22, 2022 · Past)
Chief Operating Officer · Oct 9, 2017 – Mar 14, 2018 · Past
Chau Quang Khuong
Other companies: Damora Therapeutics, Inc. (Director · Oct 28, 2020 – Jun 14, 2023 · Past); Fusion Pharmaceuticals Inc (Director · Jun 25, 2020 – Jun 14, 2023 · Past); Whitehawk Therapeutics, Inc. (Director · Jun 18, 2019 – Jun 18, 2019 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 22, 2023 · Past); Inspire Medical Systems, Inc. (Director · Apr 10, 2019 – Oct 9, 2020 · Past)
Director · Jun 5, 2019 – Apr 20, 2021 · Past
Lawrence M. Alleva
Other companies: Galera Therapeutics, Inc. (Director · Since at least Nov 6, 2019); Mersana Therapeutics Inc (Director · Since at least Sep 5, 2017); Bright Horizons Family Solutions Inc. (Board Member · Since at least May 12, 2016); Adaptimmune Therapeutics PLC (Chairman and Non-Executive Director · Since at least Jan 1, 2016); Tesaro Inc (Director · Jun 1, 2016 – Jan 22, 2019 · Past)
Director · Sep 30, 2015 – Jun 29, 2016 · Past
Anthony A Florence Jr
Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); Enliven Therapeutics, Inc. (Director · Dec 27, 2021 – Dec 27, 2021 · Past); Robinhood Markets, Inc. (Director · Jul 29, 2021 – May 2, 2022 · Past); Casper Sleep Inc (Director · Feb 6, 2020 – Jan 25, 2022 · Past)
Director · Since at least Jul 27, 2026
Aoife Brennan
Other companies: Climb Bio, Inc. (President and CEO, Director · Since at least Jun 27, 2024); Xilio Therapeutics, Inc. (Director · Since at least Jun 13, 2024); Kyntra Bio, Inc. (Director · May 26, 2021 – Jun 5, 2024 · Past)
President and CEO, Director · Mar 10, 2021 – Nov 10, 2023 · Past
Michael Powell
Other companies: Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Checkmate Pharmaceuticals Inc (Director · Aug 6, 2020 – May 31, 2022 · Past); Galera Therapeutics, Inc. (Director · Nov 6, 2019 – Jun 14, 2023 · Past)
Director · Dec 29, 2017 – Jun 5, 2019 · Past
Peter Barrett
Other companies: Obsidian Therapeutics, Inc. (Director · Since at least Aug 3, 2026); Revvity, Inc. (Partner, Atlas Venture · Since at least May 6, 2022); Larimar Therapeutics, Inc. (Director · May 10, 2022 – May 10, 2022 · Past)
Chairman, Partner, Atlas Venture · Since at least Jun 9, 2022
Gregg Beloff
Other companies: Disc Medicine, Inc. (Chief Financial Officer · Feb 5, 2021 – Feb 5, 2021 · Past); Pandion Therapeutics Inc (See Remarks · Jul 16, 2020 – Apr 1, 2021 · Past)
See Remarks · Oct 21, 2019 – Dec 6, 2021 · Past
All 20 people
PersonSeat
Michael F Burgess
Other companies: Turnstone Biologics Corp. (Interim Chief Medical Officer, Director · Jul 20, 2023 – Oct 16, 2023 · Past); SpringWorks Therapeutics Inc (Head of Research & Development · May 10, 2021 – Jul 18, 2022 · Past)
Director · Feb 3, 2020 – Jun 22, 2023 · Past
Nick Leschly
Other companies: Bluebird bio Inc (Director · Since at least Oct 2, 2020); 2Seventy Bio Inc (Director · Oct 18, 2021 – May 13, 2025 · Past)
Director · Jun 10, 2021 – Jun 22, 2023 · Past
Casi DeYoung
Other companies: Shattuck Labs, Inc. (Chief Business Officer · Since at least Oct 8, 2020)
Chief Business Officer · Sep 30, 2015 – Mar 11, 2016 · Past
Lisa Kelly-Croswell
Other companies: Eiger Biopharmaceuticals Inc (Director · Jul 18, 2022 – Mar 1, 2023 · Past)
Director · Feb 9, 2021 – Jun 22, 2023 · Past
Miguel Barbosa
Other companies: Assembly Biosciences, Inc. (See Remarks · Oct 6, 2016 – Oct 6, 2016 · Past)
Chief Scientific Officer · Sep 30, 2015 – Sep 30, 2015 · Past
Mohamad Makhzoumi
Other companies: NeueHealth Inc (Director · Since at least Oct 31, 2023)
Director · Since at least Jul 27, 2026
Antoine AwadChief Operating Officer · Jul 30, 2020 – Apr 2, 2024 · Past
Mary Beth DooleyPrincipal Executive Officer and Principal Financial Officer · Since at least Mar 18, 2024
Paul Francis MillerChief Scientific Officer · Aug 28, 2017 – Feb 12, 2019 · Past
Richard J RieseChief Medical Officer · Sep 16, 2019 – Mar 10, 2021 · Past

Open People

Log in to ask 6ix AI your own questions about Synlogic Inc.